A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Huntington Disease

In brief

The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.

Key facts

Study ID

NCT00920946

Run by

Medivation, Inc.

People needed

403

Starts

2009-07-01

Last updated by the study team

2016-10-12

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have clinical features of HD and a CAG polyglutamate repeat expansion ≥ 36
• Have cognitive impairment as noted by the following:
• A Screening MMSE AND a baseline (pre-dose) MMSE score between 10 and 26 (inclusive); and
• A subjective assessment of cognitive impairment with decline from pre-HD levels by the Investigator after interviewing the subject and caregiver;
• Are willing and able to give informed consent
• Aged 30 years or older
• Have a caregiver who assists/spends time with the subject at least five days per week for at least three hours per day and has intimate knowledge of the subject's cognitive, functional, and emotional states, and of the subject's personal care.

You may not qualify if…

• Had onset of symptoms prior to age 18
• Have any major medical illness or unstable medical condition within 180 days of screening that may interfere with the subject's ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data

Where it is running

• Study site — Scottsdale, Arizona, United States
• Study site — Davis, California, United States
• Study site — Irvine, California, United States
• Study site — La Jolla, California, United States
• Study site — San Francisco, California, United States
• Study site — Gainsville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Boise, Idaho, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Kansas City, Kansas, United States
• Study site — Wichita, Kansas, United States
• Study site — Charlestown, Massachusetts, United States
• Study site — Golden Valley, Minnesota, United States
• Study site — St Louis, Missouri, United States
• Study site — New York, New York, United States
• Study site — Rochester, New York, United States
• Study site — Durham, North Carolina, United States
• Study site — Winstom-Salem, North Carolina, United States
• Study site — Cleveland, Ohio, United States
• Study site — Columbus, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Milwaukee, Wisconsin, United States
• Study site — Wentworthville, New South Wales, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.